Bottom line
SHPCX vs BIB: the short answer
SHPCX (Health & Biotechnology Portfolio) and BIB (ProShares Ultra Nasdaq Biotechnology) are both mutual funds.
But BIB is far broader, holding 267 positions to 29 for SHPCX, so beyond the top names it adds exposure SHPCX doesn't have.
BIB is cheaper at 0.95% vs 3.6% — a difference of $265 a year per $10,000 invested.
Over five years, SHPCX returned +3.7% a year vs −1.0% for BIB (reporting dates differ).
Updated Nov 19, 2026
SHPCX vs BIB side by side
| SHPCX | BIB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Saratoga Advantage | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 3.6% | 0.95% |
| Annual cost per $10k | $360 | $95 |
| 10-yr cost on $10k (prospectus) | $3,862 | $1,401 |
| Max front load | 0% | None |
| 12b-1 fee | — | — |
| 1-yr return | −1.3% | +59.3% |
| 5-yr return (annualized) | +3.7% | −1.0% |
| 10-yr return (annualized) | +4.1% | +1.4% |
| Best quarter | +15.0% | +56.2% |
| Worst quarter | −13.0% | −42.7% |
| Net assets (fund) | $10.5M | $73.7M |
| Number of holdings | 29 | 267 |
| Portfolio turnover | 22% | 29% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SHPCX | BIB | Difference |
|---|---|---|---|
| 2024 | −0.3% | −10.0% | +9.7% |
| 2023 | −0.9% | −1.3% | +0.3% |
| 2022 | +1.4% | −28.6% | +30.0% |
| 2021 | +16.0% | −5.9% | +21.9% |
| 2020 | +3.0% | +39.7% | −36.7% |
| 2019 | +15.4% | +45.5% | −30.1% |
| 2018 | −6.0% | −24.4% | +18.4% |
| 2017 | +11.3% | +40.8% | −29.5% |
| 2016 | −2.5% | −44.2% | +41.7% |
Source: Fund prospectus bar charts
Holdings overlap
6 of SHPCX's top 25 holdings also appear in BIB's top 25.
| Holding | SHPCX | BIB |
|---|---|---|
| United Therapeutics Corp | 6.17% | 1.22% |
| Amgen Inc | 5.04% | 4.48% |
| Gilead Sciences Inc | 3.94% | 4.66% |
| Regeneron Pharmaceuticals Inc | 3.93% | 3.21% |
| Vertex Pharmaceuticals Inc | 3.36% | 4.65% |
| Incyte Corp | 2.89% | 0.97% |
Source: SEC Form N-PORT
SHPCX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between SHPCX and BIB?
Which is cheaper, SHPCX or BIB?
Should I own both SHPCX and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.